NCT06179524View on ClinicalTrials.gov

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

April 30, 2027

Conditions
Relapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CAR-T-19 cell injection

The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.

Trial Locations (1)

Unknown

RECRUITING

Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Beijing Yongtai Ruike Biotechnology Company Ltd

INDUSTRY